Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual

Homepage

Finance

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual

Related

Trump says there could be more US strikes in Nigeria, New Yo...

Form 144 MP MATERIALS CORP. For: 8 January

Form 144 IDT CORPORATION For: 8 January

Trending

Popular

College football by the odds: Vegas picks and preview of Ohi...

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

Australian whose blood saved 2.4 million babies dies

What to do in Las Vegas this week: January 2-8